CoChat

Long-term outcomes of breast cancer in women aged 30 years or younger, based on family history, pathology and BRCA1/BRCA2/TP53 status

Open access
Evans, D G R, Moran, A, Hartley, R, Dawson, J, Bulman, B, Knox, F, Howell, A, Lalloo, F · 2010 · British Journal of Cancer

The DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index; none of the 24 sources its claims cite is checked for support yet.

Abstract

BACKGROUND: There are relatively few articles addressing long-term follow-up in women with breast cancer at very young ages. METHODS: We have updated and extended our population-based analysis of breast cancer diagnosed at the age < or =30 years in North-west England to include an extra 15 patients with mutation testing in BRCA1, BRCA2 and TP53, with 115 of 288 consecutive cases being tested. Kaplan-Meier curves were generated to assess overall survival, contralateral breast cancer and other second primaries. RESULTS: Survival analysis of all 288 patients showed poor overall survival, although this improved from a 15-year survival of only 46% in those diagnosed between 1980 and 1989 to 58% in those diagnosed between 1990 and 1997 (P=0.05). Contralateral breast cancer rates were at a steady rate of 0.6 per 1000, although the rates in mutation carriers were approximately 2 per 1000. Altogether, 16 BRCA1, 9 BRCA2 and 6 TP53 mutations have now been found among the 115 cases on whom DNA analysis has been performed. BRCAPRO accurately predicted the number of carriers for BRCA1 and BRCA2 and was sensitive and specific at the 10 and 20% threshold, respectively. However, BRCAPRO did not seem to give any weight to DCIS, which accounted for two BRCA1 carriers and three TP53 carriers and overpredicted mutations at the high end of the spectrum, with only 6 of 11 (54%) with a >90% probability having identifiable BRCA1/2 mutations. INTERPRETATION: Rates of new primaries are predicted to some extent by mutation status. BRCAPRO is useful at determining those patients aged < or =30 years to be tested.

Overview

CoChat Summary

## TL;DR

This population-based study of women diagnosed with breast cancer at age ≤30 years found poor long-term survival overall, with improvement over time and contralateral breast cancer occurring at about 0.6% per year. Mutation status and family history mattered: BRCA1, BRCA2, and TP53 mutations accounted for a substantial fraction of familial cases, and BRCAPRO was useful for identifying women in this age group who should be tested.

## Key findings

  • Among all 288 patients, 15-year survival improved from 46% in those diagnosed in 1980–1989 to 58% in those diagnosed in 1990–1997 (P=0.05); in the post-1990 group, 5-, 10-, and 15-year survival was 69%, 58%, and 57%, compared with 61%, 49%, and 46% before 1990.
  • Contralateral breast cancer incidence was 0.6% per year up to 20 years of follow-up; in the enriched mutation-carrier dataset, the annual risk was about 2% up to 15 years, with 19 contralateral cancers observed in follow-up.
  • Pathogenic mutations were found in 31 women among the tested cohort: 16 BRCA1, 9 BRCA2, and 5 TP53; in the molecular analysis, mutations occurred in 26 of 53 (49%) familial cases versus 5 of 62 (8%) non-familial cases.
  • BRCAPRO “accurately predicted” BRCA1/2 carriers overall and was sensitive and specific at the 10% and 20% thresholds, respectively, but it appeared to ignore DCIS and overpredicted at the high end: only 6 of 11 (54%) women with >90% predicted BRCA1/2 probability had an identifiable BRCA1/2 mutation.

## Methods

  • Population-based follow-up of consecutive breast cancers diagnosed at age ≤30 years in North-west England/NWCIS between 1 January 1980 and 31 December 1997; the original series included 288 patients, and genetic status was established for 115 women, with 15 additional mutation-tested samples added since the previous report.
  • Mutation testing covered BRCA1, BRCA2, and TP53; pathology review used original reports and a single pathologist review where tissue was available, with ER/PR/HER2 assessed by immunohistochemistry when possible.
  • Main analyses used Kaplan–Meier curves for overall survival, contralateral breast cancer, and other second primaries, with χ² tests comparing groups and 95% confidence intervals for survival and contralateral tumour incidence; model performance for BRCAPRO, Myriad, and the Manchester score was assessed at 10% and 20% thresholds.

## Limitations

  • The paper states that pathology reports before 1990 had little information on grade and no hormone receptor status, making reliable survival analysis by tumour grade impossible for those cases.
  • The study also notes that some comparisons are limited by small numbers, especially for later contralateral cancer estimates in mutation carriers and high-probability model strata.
  • Evident from the text: mutation testing was not performed on all 288 cases, so some mutation-status analyses are based on a subset rather than the full cohort.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/sj.bjc.6605606

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Survival from breast cancer diagnosis in 288 breast cancer cases aged ⩽30 years and diagnosed between 1980 and 1997.
Figure 1 Survival from breast cancer diagnosis in 288 breast cancer cases aged ⩽30 years and diagnosed between 1980 and 1997.CC BY · PubMed Central
Figure 2 (A) Contralateral breast cancer cumulative incidence in all incident breast cancer cases aged ⩽30 years. (B) Contralateral breast cancer cumulative incidence in BRCA1, BRCA2 and TP53 breast cancer cases at ⩽30 years of age and in mutation-negative groups.
Figure 2 (A) Contralateral breast cancer cumulative incidence in all incident breast cancer cases aged ⩽30 years. (B) Contralateral breast cancer cumulative incidence in BRCA1, BRCA2 and TP53 breast cancer cases at ⩽30 years of age and in mutation-negative groups.CC BY · PubMed Central

Verification

Claims the paper makes

0 Valid · 0 Not valid · 16 Not checked · 59 Own results and interpretations

43 more claims

Create a free account to see all 75 claims and to verify the 24 references still open.

See all claims — free account
  • It may state two separate claims as one. 21
  • Probably not a substantial claim. 9

Create a free account to see these claims.

Citations

Cites

Show all 28 references

Cited by

See all 52

Metadata

Authors
Evans, D. G. R., Moran, A., Hartley, R., Dawson, J., Bulman, B., Knox, F., Howell, A., & Lalloo, F.
Affiliations
  • Manchester Academic Health Science Centre (GB)
  • The Christie NHS Foundation Trust (GB)
  • Wythenshawe Hospital (GB)
  • University of Manchester (GB)
Corresponding author
Evans, D G R
Venue
British Journal of Cancer
Published
2010-03
Volume
102
Issue
7
Pages
1091-1098
ISSN
  • 0007-0920 (ISSN-L)
  • 1532-1827
OpenAlex
W2138346386
Cited by
52
References
29
Citations by year
2025: 5 · 2024: 2 · 2021: 6 · 2020: 3 · 2019: 4 · 2018: 2 · 2017: 6 · 2016: 2 · 2015: 10 · 2014: 3 · 2013: 2 · 2012: 3
FWCI
1.62
Type
journal article
Language
en
Open access
Locations
  • British Journal of Cancer (publishedVersion, cc-by-nc-sa)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Research Explorer (The University of Manchester) (publishedVersion)
Funders
National Institute for Health and Care Research
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
  • Health Sciences › Medicine › Epidemiology › Multiple and Secondary Primary Cancers
Keywords
breast cancer, young women, BRCA1, BRCA2, TP53, germline mutation testing, BRCAPRO, family history (medicine), overall survival, contralateral breast cancer, secondary malignancies, ductal carcinoma in situ, long-term outcomes
MeSH terms
Adult, Breast Neoplasms, England, Female, Follow-Up Studies, Genetic Testing, Humans, Models, Biological, Mutation, Cohort Studies, Survival Analysis, Genes, p53, Survivors, Genes, BRCA1, Genetic Predisposition to Disease, Genes, BRCA2, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Long-term outcomes of breast cancer in women aged 30 years or younger, based on family history, pathology and BRCA1/BRCA2/TP53 status. https://app.cochat.ai/papers/10.1038/sj.bjc.6605606
The paper
Evans, D. G. R., Moran, A., Hartley, R., Dawson, J., Bulman, B., Knox, F., Howell, A., & Lalloo, F. (2010). Long-term outcomes of breast cancer in women aged 30 years or younger, based on family history, pathology and BRCA1/BRCA2/TP53 status. British Journal of Cancer. https://doi.org/10.1038/sj.bjc.6605606

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.